Pfizer Wins Viagra Patent Trial Against Teva Pharmaceuticals

Pfizer Inc. PFE announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. TEVA in the United States District Court for the Eastern District of Virginia. The court's decision, which is subject to appeal, prevents Teva from receiving approval for a generic form of Viagra until October 2019. Litigation on the same patent remains pending against other generic companies, but no trials are scheduled in those other cases.